Protocol: **CF (Cisplatin/5-Fluorouracil)**

**Indications:** Head and neck – metastatic, recurrent

**Schedule:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>iv/infusion/oral</th>
<th>q</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisplatin</td>
<td>100mg/m²</td>
<td>1L N. Saline/2hrs</td>
<td>Day 1</td>
</tr>
<tr>
<td>5-Fluorouracil</td>
<td>1g/m²/24hrs</td>
<td>continuous infusion</td>
<td>Days 1-5</td>
</tr>
</tbody>
</table>

**Cycle frequency:** Every three weeks  
**Total number of cycles:** 4-6

**Dose modifications:** Discuss with Consultant

**Administration and safety:**
- Anti-emetic group – High
- Delay if neutrophils < 1.5 x 10⁹/L or platelets < 100 x 10⁹/L
- Ensure adequate renal function
- Pre & post hydration, mannitol, potassium & magnesium

**Toxicities:** Myelosuppression and risk of neutropenic sepsis or haemorrhage, nausea & vomiting, mucositis, alopecia, cardiotoxicity, peripheral neuropathy, palmar-plantar syndrome, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility

**Symptomatic treatment of side effects:** Mouth care, anti-diarrheals, pyridoxine

**Investigations**

**Pre-treatment:**
- History and Examination
- Performance score, weight
- FBC
- U & E’s, LFTs, Mg²⁺, Ca²⁺, creatinine, urate, creatinine clearance
- LDH
- ECG
- Staging investigations as per protocol

**Prior to each cycle:**
- Performance score, weight
- FBC
- U & E’s, LFTs, Mg²⁺, Ca²⁺, creatinine
- LDH

**Mid Treatment:** Re-assess after 2 cycles

**Post Treatment:** Review in Medical Oncology Clinic 4 weeks after last cycle

Protocol: Modified BEC (Bleomycin/Epirubicin/Cisplatin)

Indications: Nasopharyngeal tumours - neoadjuvant

Schedule:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>iv/infusion/oral</th>
<th>q</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bleomycin</td>
<td>30,000iu</td>
<td>200mls N. Saline/30mins</td>
<td>Day 2</td>
</tr>
<tr>
<td>Epirubicin</td>
<td>70mg/m²</td>
<td>iv</td>
<td>Day 1</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>50mg/m²</td>
<td>1L N. Saline/4hrs</td>
<td>Days 1 &amp; 2</td>
</tr>
<tr>
<td>Bleomycin</td>
<td>30,000iu</td>
<td>200mls N. Saline/30mins</td>
<td>Days 8 &amp; 15</td>
</tr>
</tbody>
</table>

Cycle frequency: Every three weeks Total number of cycles: 3

Dose modifications: Discuss with Consultant

Administration and safety:
- Anti-emetic group – High
- Delay if neutrophils < 1.0 x 10⁹/L or platelets < 100 x 10⁹/L
- Ensure adequate renal function
- Pre & post hydration, mannitol, potassium & magnesium

Toxicities: Myelosuppression and risk of neutropenic sepsis or haemorrhage, nausea & vomiting, mucositis, alopecia, peripheral neuropathy, nephrotoxicity, ototoxicity, pneumonitis, constipation, diarrhoea, carcinogenesis, infertility

Symptomatic treatment of side effects: Mouth care, encourage oral fluids

Investigations

Pre-treatment:
- History and Examination
- Performance score, weight
- FBC
- U & E’s, LFTs, Mg²⁺, Ca²⁺, creatinine, urate, creatinine clearance,
- LDH
- ECG, lung function (inc. DLCO), CXR, Audiometry
- Staging investigations as per protocol

Prior to each cycle (and Day 8 & 15 Bleomycin):
- Performance score, weight
- FBC
- U & E’s, LFTs, Mg²⁺, Ca²⁺, creatinine
- LDH
- CXR (Day 1 only)

Post Treatment: Review in Medical Oncology Clinic 3 weeks after last cycle